Hyphens Pharma International Limited

Catalist:1J5 Stock Report

Market Cap: S$89.6m

Hyphens Pharma International Past Earnings Performance

Past criteria checks 5/6

Hyphens Pharma International has been growing earnings at an average annual rate of 10.5%, while the Pharmaceuticals industry saw earnings growing at 9.4% annually. Revenues have been growing at an average rate of 10.7% per year. Hyphens Pharma International's return on equity is 15.1%, and it has net margins of 5.3%.

Key information

10.5%

Earnings growth rate

9.9%

EPS growth rate

Pharmaceuticals Industry Growth12.4%
Revenue growth rate10.7%
Return on equity15.1%
Net Margin5.3%
Last Earnings Update30 Sep 2024

Recent past performance updates

Recent updates

Revenue & Expenses Breakdown

How Hyphens Pharma International makes and spends money. Based on latest reported earnings, on an LTM basis.


Earnings and Revenue History

Catalist:1J5 Revenue, expenses and earnings (SGD Millions)
DateRevenueEarningsG+A ExpensesR&D Expenses
30 Sep 2419710500
30 Jun 2419610520
31 Mar 2418510500
31 Dec 231719500
30 Sep 231567480
30 Jun 231569480
31 Mar 2315610480
31 Dec 2216211480
30 Sep 2215612400
30 Jun 221439430
31 Mar 221328400
31 Dec 211267400
30 Sep 211266370
30 Jun 211236390
31 Mar 211266370
31 Dec 201216370
30 Sep 201267360
30 Jun 201258360
31 Mar 201247350
31 Dec 191197350
30 Sep 191176330
30 Jun 191155320
31 Mar 191175320
31 Dec 181215310
30 Sep 181175320
30 Jun 181176300
31 Mar 181156290
31 Dec 171136290
31 Dec 161015290
31 Dec 15785190

Quality Earnings: 1J5 has high quality earnings.

Growing Profit Margin: 1J5's current net profit margins (5.3%) are higher than last year (4.3%).


Free Cash Flow vs Earnings Analysis


Past Earnings Growth Analysis

Earnings Trend: 1J5's earnings have grown by 10.5% per year over the past 5 years.

Accelerating Growth: 1J5's earnings growth over the past year (54.8%) exceeds its 5-year average (10.5% per year).

Earnings vs Industry: 1J5 earnings growth over the past year (54.8%) exceeded the Pharmaceuticals industry 7.5%.


Return on Equity

High ROE: 1J5's Return on Equity (15.1%) is considered low.


Return on Assets


Return on Capital Employed


Discover strong past performing companies